{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:29:44Z","timestamp":1723595384451},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Inform Decis Mak"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background and Aims<\/jats:title>\n                <jats:p>Systematic reviews and medical guidelines are widely used in clinical practice. However, these are often not up-to-date and focussed on the average patient. We therefore aimed to evaluate a guideline add-on, TherapySelector (TS), which is based on monthly updated data of all available high-quality studies, classified in specific patient profiles.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We evaluated the TS for the treatment of hepatitis C (HCV) in an international cohort of patients treated with direct-acting antivirals between 2015 and 2020. The primary outcome was the number of patients receiving one of the two preferred treatment options of the HCV TS, based on the highest level of evidence, cure rate, absence of ribavirin-associated adverse effects, and treatment duration.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We enrolled 567 patients. The number of patients treated with one of the two preferred treatment options according to the HCV TS ranged between 27% (2015) and 60% (2020; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Most of the patients received a regimen with a longer treatment-duration (up to 34%) and\/or addition of ribavirin (up to 14%). The effect on the expected cure-rate was minimal (1\u20136% higher) when the first preferred TherapySelector option was given compared to the actual treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Medical decision-making can be optimised by a guideline add-on; in HCV its use appears to minimise adverse effects and cost. The use of such an add-on might have a greater impact in diseases with suboptimal cure-rates, high costs or adverse effects, for which treatment options rely on specific patient characteristics.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12911-024-02608-x","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T09:02:20Z","timestamp":1723539740000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient profiled data for treatment decision-making: valuable as an add-on to hepatitis C clinical guidelines?"],"prefix":"10.1186","volume":"24","author":[{"given":"Sylvia M.","family":"Brakenhoff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thymen","family":"Theijse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"van Wijngaarden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Trautwein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan F.","family":"Brozat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Tacke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter","family":"Honkoop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Vanwolleghem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Posthouwer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Mihm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solko W.","family":"Schalm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"de Knegt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,13]]},"reference":[{"issue":"3","key":"2608_CR1","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1177\/014107680309600304","volume":"96","author":"KS Khan","year":"2003","unstructured":"Khan KS, Kunz R, Kleijnen J, et al. Five steps to conducting a systematic review. J R Soc Med. 2003;96(3):118\u201321.","journal-title":"J R Soc Med"},{"issue":"1","key":"2608_CR2","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1093\/jamia\/ocw042","volume":"24","author":"BA Goldstein","year":"2017","unstructured":"Goldstein BA, Navar AM, Pencina MJ, et al. Opportunities and challenges in developing risk prediction models with electronic health records data: a systematic review. J Am Med Inform Assoc. 2017;24(1):198\u2013208.","journal-title":"J Am Med Inform Assoc"},{"issue":"1","key":"2608_CR3","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13643-018-0856-9","volume":"7","author":"R Bashir","year":"2018","unstructured":"Bashir R, Surian D, Dunn AG. Time-to-update of systematic reviews relative to the availability of new evidence. Syst Rev. 2018;7(1):195.","journal-title":"Syst Rev"},{"issue":"Suppl 2","key":"2608_CR4","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1097\/BPO.0b013e31824b6e1c","volume":"32","author":"KG Shea","year":"2012","unstructured":"Shea KG, Sink EL, Jacobs JC Jr. Clinical practice guidelines and guideline development. J Pediatr Orthop. 2012;32(Suppl 2):S95-100.","journal-title":"J Pediatr Orthop"},{"key":"2608_CR5","volume-title":"Oproep indienen projectidee\u00ebn: Innovatie van Richtlijnen","author":"ZonMw","year":"2019","unstructured":"ZonMw. Oproep indienen projectidee\u00ebn: Innovatie van Richtlijnen. 2019."},{"key":"2608_CR6","unstructured":"U.S. Food & Drug Administration. Available via https:\/\/www.fda.gov\/."},{"key":"2608_CR7","unstructured":"European Medicines Agency. Available via https:\/\/www.ema.europa.eu\/en."},{"key":"2608_CR8","unstructured":"TherapySelector. https:\/\/therapyselector.nl\/."},{"issue":"1","key":"2608_CR9","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","volume":"63","author":"European Association for Study of L","year":"2015","unstructured":"European Association for Study of L. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015;63(1):199\u2013236.","journal-title":"J Hepatol"},{"issue":"1","key":"2608_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","volume":"66","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. Electronic address eee. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2017;66(1):153\u201394.","journal-title":"J Hepatol"},{"issue":"2","key":"2608_CR11","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","volume":"69","author":"Association for the Study of the Liver","year":"2018","unstructured":"Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69(2):461\u2013511.","journal-title":"J Hepatol"},{"issue":"3","key":"2608_CR12","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/1468-0009.12210","volume":"94","author":"JP Ioannidis","year":"2016","unstructured":"Ioannidis JP. The Mass Production of Redundant, Misleading, and Conflicted Systematic Reviews and Meta-analyses. Milbank Q. 2016;94(3):485\u2013514.","journal-title":"Milbank Q"}],"container-title":["BMC Medical Informatics and Decision Making"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12911-024-02608-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12911-024-02608-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12911-024-02608-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T09:07:56Z","timestamp":1723540076000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedinformdecismak.biomedcentral.com\/articles\/10.1186\/s12911-024-02608-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,13]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2608"],"URL":"https:\/\/doi.org\/10.1186\/s12911-024-02608-x","relation":{},"ISSN":["1472-6947"],"issn-type":[{"value":"1472-6947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,13]]},"assertion":[{"value":"13 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No informed consent was required, as anonymised patient data was used in the analyses, in according to the laws for the protection of privacy (AVG). The study was conducted in accordance with the guidelines of the declaration of Helsinki and the principles of Good Clinical Practice. The study was approved by the Institutional Review Board of the Erasmus MC (MEC-2020\u20130751).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Frank Tacke received research grants from Gilead, Allergan, Bristol-Myers Squibb, and Inventiva. Thomas VanWolleghem has received grants from Gilead Sciences, Roche, and Bristol Myers Squibb; served as a consultant for Janssen Pharmaceuticals, Gilead Sciences, AbbVie, Bristol Myers Squibb; and served as a sponsored lecturer for W.L. Gore, Gilead Sciences, and Bristol Myers Squibb. Stefan Zeuzem has received speaking and\/or consulting fees from Abbvie, BioMarin, Gilead, GSK, Intercept, Janssen, Merck\/MSD, NovoNordisk, SoBi, and Theratechnologies. Heiner Wedemeyer has received research grants from AbbVie, Biotest, Gilead Sciences, Merck Sharp and Dohme, and Roche; consultancy fees from AbbVie, Aligos, Altimmune, Biotest, Bristol-Myers Squibb, BTG, Dicerna, Enanta, Gilead Sciences, Janssen, Merck Sharp and Dohme, MYR GmbH, Roche and Vir Biotechnology; honoraria from AbbVie, Biotest, Gilead Sciences and Merck Sharp and Dohme; funds from AbbVie, Altimmune, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp and Dohme, MYR GmbH, Novartis and Vir Biotechnology as principal investigator for clinical trials. Christian Trautwein Received grants\/research support from Abbvie, BMS, Gilead, Intercept, Merz, Norgine, Novartis. Received honoraria\/consultation fees or served on the advisory board for Bayer, Gilead, GSK, Falk Foundation, Intercept and Roche.Frank Tacke received research grants from Gilead, Allergan, Bristol-Myers Squibb, and Inventiva. Thomas VanWolleghem has received grants from Gilead Sciences, Roche, and Bristol Myers Squibb; served as a consultant for Janssen Pharmaceuticals, Gilead Sciences, AbbVie, Bristol Myers Squibb; and served as a sponsored lecturer for W.L. Gore, Gilead Sciences, and Bristol Myers Squibb. Stefan Zeuzem has received speaking and\/or consulting fees from Abbvie, BioMarin, Gilead, GSK, Intercept, Janssen, Merck\/MSD, NovoNordisk, SoBi, and Theratechnologies. Heiner Wedemeyer has received research grants from AbbVie, Biotest, Gilead Sciences, Merck Sharp and Dohme, and Roche; consultancy fees from AbbVie, Aligos, Altimmune, Biotest, Bristol-Myers Squibb, BTG, Dicerna, Enanta, Gilead Sciences, Janssen, Merck Sharp and Dohme, MYR GmbH, Roche and Vir Biotechnology; honoraria from AbbVie, Biotest, Gilead Sciences and Merck Sharp and Dohme; funds from AbbVie, Altimmune, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp and Dohme, MYR GmbH, Novartis and Vir Biotechnology as principal investigator for clinical trials. Christian Trautwein Received grants\/research support from Abbvie, BMS, Gilead, Intercept, Merz, Norgine, Novartis. Received honoraria\/consultation fees or served on the advisory board for Bayer, Gilead, GSK, Falk Foundation, Intercept and Roche. Thomas Berg received grants\/research support from Abbvie, BMS, Gilead, MSD\/Merck, Humedics, Intercept, Merz, Norgine, Novartis, Orphalan, and Sequana Medical; received honoraria\/consultation fees or served on the advisory board for Abbvie, Alexion, Bayer, Gilead, GSK, Eisai, Enyo Pharma, Falk Foundation, HepaRegeniX GmbH, Humedics, Intercept, Ipsen, Janssen, MSD\/Merck, Novartis, Orphalan, Roche, Sequana Medical, SIRTEX, SOBI, and Shionogi; participated in a company-sponsored speaker\u2019s bureau for Abbvie, Alexion, Bayer, Gilead, Eisai, Intercept, Ipsen, Janssen, MedUpdate GmbH, MSD\/Merck, Novartis, Orphalan, Sequana Medica, SIRTEX, and SOBI. Rob de Knegt has received honoraria for consulting\/speaking from Gilead, Janssen, Echosens, AbbVie, and Norgine and received research grants form Gilead and Janssen. The other authors have no conflict of interest in relation to the contents of this manuscript.Thomas Berg received grants\/research support from Abbvie, BMS, Gilead, MSD\/Merck, Humedics, Intercept, Merz, Norgine, Novartis, Orphalan, and Sequana Medical; received honoraria\/consultation fees or served on the advisory board for Abbvie, Alexion, Bayer, Gilead, GSK, Eisai, Enyo Pharma, Falk Foundation, HepaRegeniX GmbH, Humedics, Intercept, Ipsen, Janssen, MSD\/Merck, Novartis, Orphalan, Roche, Sequana Medical, SIRTEX, SOBI, and Shionogi; participated in a company-sponsored speaker\u2019s bureau for Abbvie, Alexion, Bayer, Gilead, Eisai, Intercept, Ipsen, Janssen, MedUpdate GmbH, MSD\/Merck, Novartis, Orphalan, Sequana Medica, SIRTEX, and SOBI. Rob de Knegt has received honoraria for consulting\/speaking from Gilead, Janssen, Echosens, AbbVie, and Norgine and received research grants form Gilead and Janssen. Solko Schalm is the unpaid director of TherapySelector B.V., a socially oriented company that has developed the TherapySelector instrument. Neither he nor the company was involved in the design, funding, conduct or data analysis of the study. He provided the TherapySelector instrument information, was helpful in providing access to the annual editions of the database and gave suggestions about the manuscript text. Neither he nor the Therapy Selector company have received any financial contribution from pharmaceutical companies. The other authors have no conflict of interest in relation to the contents of this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"227"}}